3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
4
Neoplasm Metastasis
3
Urethral Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma
1
Interventions
Kidney Transplantation
3
Paclitaxel
2
Carboplatin
2
vinflunine
1
veliparib
1
trifluridine tipiracil drug combination
1
trebananib
1
ripretinib
1
pembrolizumab
1
belantamab mafodotin
1
Zoledronic Acid
1
Urination
1
Taxes
1
Stents
1
Standard of Care
1
Sitagliptin Phosphate
1
Polymerase Chain Reaction
1
Oxaliplatin
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Ice
1
Health Information Exchange
1
Gemcitabine
1
Duration of Therapy
1
Cyclosporine
1
Cyclophosphamide
1
Blood Specimen Collection
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Renal Insufficiency
×
vinflunine
×
Genitourinary
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled